Plant Compound, Arbutin, Eases Some Symptoms in Parkinson’s Mouse Model, Study Shows

Arbutin, a natural compound found in plants such as bearberry leaves and pear trees, was able to protect dopaminergic neurons and reduce behavioral deficits and oxidative stress in an animal model of Parkinson’s disease, a study reports. The study, “Arbutin attenuates behavioral impairment and oxidative stress in an animal model of Parkinson’s disease,” was published

PF-06412562 Safe, Eases Motor Impairments in Parkinson’s Patients, Phase 1 Trial Finds

A compound that targets two specific dopamine receptors in the brain is safe and can ease motor deficits in Parkinson’s patents, recent clinical data reveals. The study, “Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson’s Disease following Oral Administration,” was published in Neurodegenerative Diseases. Pharmacological treatment of Parkinson’s patients mostly has used the dopamine precursor levodopa

Staying Active Versus Exercise

Whether you ask a group of people with Parkinson’s disease (PD) or your neurologist about the best thing you can do to keep PD at bay or slow down its symptoms, the most common response will likely be “exercise.” Some may say, “Stay active.” But do you realize that staying active and exercising are two

Discovery of New Brain Region Could Have Implications for Neurodegenerative Disorders

The recent discovery of a previously unknown region of the human brain could have significant implications for neurodegenerative disorders affecting motor skills, such as Parkinson’s disease and motor neuron diseases including amyotrophic lateral sclerosis and spinal muscular atrophy Neuroscientist George Paxinos’ discovery of the endorestiform nucleus, which functions to control fine motor skills, is detailed in

Exercise That Motivates Parkinson’s Patients to Push Limits Can Offer Range of Benefits, Experts Say

With a treatment not yet within reach that might slow the progression of Parkinson’s disease, much less offer a cure, many — doctors, patients, and researchers alike — are looking to exercise in hopes of fending off a worsening of symptoms. Interest in exercise-based interventions has risen so much that “the number of publications on exercise studies

Mission, Abbvie Partner to Develop DUB Enzyme Inhibitors for Parkinson’s and Alzheimer’s

Mission Therapeutics and AbbVie have established a new partnership aimed at developing specific inhibitors targeting deubiquitylating enzymes, or DUBs, for the treatment of Alzheimer’s and Parkinson’s diseases. DUBs are a large family of important enzymes that regulate the protein degradation process, some of which are involved in the destruction of misfolded and potentially toxic proteins known to be

Deterioration of Nerve Cell Structure Not the Main Cause of Early Parkinson’s Symptoms, Mouse Study Suggests

Although the structure of dopaminergic neurons gradually deteriorates before cell death, these alterations do not seem to account for the subtle impairments seen during the early stages of Parkinson’s disease, a mouse study has found. The study, “Progressively Disrupted Somatodendritic Morphology in Dopamine Neurons in a Mouse Parkinson’s Model,” was published in Movement Disorders. Parkinson’s is

PF-360 Provides Some Benefits But Does Not Improve Dopaminergic Function, Mouse Study Shows

Treatment with PF-360, an investigational leucine-rich repeat kinase 2 (LRRK2) inhibitor, can efficiently decrease LRRK2’s phosphorylation levels, known to be elevated in Parkinson’s patients, in the brains of a mouse model of Parkinson’s disease, a preclinical study reports. However, despite some observed dose-dependent therapeutic effects, including gait improvement, no robust changes in dopaminergic function were observed. Results